Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Evaxion Receives FDA Fast-track Designation for Personalized Cancer Immunotherapy
Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today […]
BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia
BeiGene, a global biotechnology company, today announced that the United States Food and Drug Administration […]
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing […]
Neochromosome and Sumitovant Biopharma Announce Successful Collaboration to Accelerate Protein Drug Discovery and Improve Manufacturing
Neochromosome, a wholly owned subsidiary of Opentrons Labworks, focused on changing the world of biologics […]
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma
Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of […]
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Sun Pharma and Concert Pharmaceuticals today announced that they have executed a definitive agreement under […]
Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
Tallac Therapeutics, a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity […]
Scenic Biotech Strengthens Drug Discovery Expertise in Management Team with the Addition of Kristof Van Emelen
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe […]
VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative […]
First Patient Dosed in CANbridge Pharmaceuticals Trial for the Treatment of Gaucher Disease in China
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more